2022 annual financial data
Relmada Therapeutics 2022 Operating margin
Relmada Therapeutics 2022 operating margin with verified reported values.
Direct answer
Operating margin was Not calculable.
Operating income was -161,249,000 USD and net income was -157,043,000 USD.
Operating cash flow was -103,801,617 USD.
Get free Relmada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -161,249,000 USD
- Net income
- -157,043,000 USD
- Operating cash flow
- -103,801,617 USD